Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Erbil Polytechnic University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07120828CT.gov The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity | — | Completed | — | — | — |
NCT06762314CT.gov Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes | — | Recruiting | — | — | — |
NCT04583813CT.gov Empagliflozin and Atrial Fibrillation Treatment | — | Unknown | — | — | — |
NCT04702490CT.gov Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diabetes Mellitus
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Empagliflozin (this asset) | Erbil Polytechnic University | Approved | BB · 68 |
| Metformin | Erbil Polytechnic University | P4 | A |
| Pioglitazone | Milton S. Hershey Medical Center | P4 | BBB |
| Alogliptin | Takeda | P3 | BBB |
| Glibenclamide | Takeda | P4 | BBB |
| Aspirin | Region Skane | P4 | BBB |
| Sitagliptin | Second Affiliated Hospital of Soochow University | P4 | BBB |
| Semaglutide | LMC Diabetes & Endocrinology Ltd. | P4 | BB |
| Ezetimibe | University of Oxford | P4 | BB |
+41 more in the Diabetes Mellitus cohort
Other indications for Empagliflozin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prediabetes Syndrome | — | P4 | BBB · 74 |
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | P4 | BBB · 73 |
| Type 2 Diabetes Mellitus | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Empagliflozin in Diabetes Mellitus. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/empagliflozin-diabetes-mellitus
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →